Moderate
Established
विवरण
Lansoprazole, like omeprazole, inhibits CYP2C19 and reduces clopidogrel's antiplatelet efficacy, potentially increasing cardiovascular event risk.
तंत्र
Lansoprazole inhibits CYP2C19, reducing the formation of clopidogrel's active thiol metabolite and impairing P2Y12 receptor blockade.
नैदानिक महत्व
FDA and EMA communications note reduced platelet inhibition; pantoprazole is preferred when gastroprotection is needed.
प्रबंधन
Switch to pantoprazole if PPI is needed in clopidogrel-treated patients; if lansoprazole must be used, monitor for cardiovascular events.